SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-245346
Filing Date
2019-09-16
Accepted
2019-09-16 07:09:03
Documents
14
Period of Report
2019-09-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d804595d8k.htm   iXBRL 8-K 32995
2 EX-99.1 d804595dex991.htm EX-99.1 20418
6 GRAPHIC g8045952.jpg GRAPHIC 13706
  Complete submission text file 0001193125-19-245346.txt   204537

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20190914.xsd EX-101.SCH 3075
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20190914_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20190914_pre.xml EX-101.PRE 11411
11 EXTRACTED XBRL INSTANCE DOCUMENT d804595d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 191093736
SIC: 2834 Pharmaceutical Preparations